Skip to main content

BioCorRx Inc. (BICX)

OTCMKTS: BICX · Delayed Price · USD
4.65 -0.01 (-0.21%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap31.11M
Revenue (ttm)77,873
Net Income (ttm)-3.41M
Shares Out6.69M
EPS (ttm)-0.72
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume260
Open4.65
Previous Close4.66
Day's Range4.65 - 4.65
52-Week Range0.16 - 8.10
Beta1.02
Analystsn/a
Price Targetn/a
Earnings DateNov 15, 2021

About BICX

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The...

IndustryMedical Care Facilities
CEOBrady Granier
Employees3
Stock ExchangeOTCMKTS
Ticker SymbolBICX
Full Company Profile

News

BioCorRx to Participate in the Benzinga All Access Event on December 2nd

ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related ...

2 weeks ago - GlobeNewsWire

BioCorRx Acquires Intellectual Property for Drug Delivery

Patent Application Covers Solid Implant Formulation for Drug Delivery

2 weeks ago - GlobeNewsWire

BioCorRx Provides Business Update for the Third Quarter of 2021

ANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

3 weeks ago - GlobeNewsWire

BioCorRx to Present at the Q4 Investor Summit Conference on November 16th

Anaheim, California--(Newsfile Corp. - November 10, 2021) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorde...

4 weeks ago - Newsfile Corp

BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant

ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorde...

2 months ago - GlobeNewsWire

BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th

ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disord...

2 months ago - GlobeNewsWire

BioCorRx Files Patent Application with USPTO for Naltrexone Implant

ANAHEIM, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorder...

2 months ago - GlobeNewsWire

Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pe...

SAN DIEGO, CA, and ANAHEIM, CA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to...

3 months ago - GlobeNewsWire

BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable ...

On track to commence the first-in-human clinical trial for BICX104

3 months ago - GlobeNewsWire

BioCorRx Provides Business Update for the Second Quarter of 2021

ANAHEIM, CA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorde...

3 months ago - GlobeNewsWire

BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board

ANAHEIM, CA, June 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substanc...

5 months ago - GlobeNewsWire

BioCorRx Provides Business Update for the First Quarter of 2021

ANAHEIM, CA, May 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --  BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substanc...

6 months ago - GlobeNewsWire

BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone

ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substan...

7 months ago - GlobeNewsWire

BioCorRx Provides 2020 Year-End Business Update

ANAHEIM, CA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorder...

8 months ago - GlobeNewsWire

BioCorRx Completes $2.25 Million Private Placement

ANAHEIM, CA, March 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorder...

9 months ago - GlobeNewsWire

BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol...

ANAHEIM, CA, Jan. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders...

10 months ago - GlobeNewsWire